OCGN - Ocugen, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Ocugen, Inc.

263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
484 328 4701

Full-time employees84

Key executives

NameTitlePayExercisedYear born
Dr. Shankar Musunuri M.B.A., MBA, Ph.D.Co-Founder, Chairman & CEO1.2M1.26M1964
Dr. Uday B. Kompella Ph.D.Co-founder & Independent Director56.72kN/A1967
Mr. Quan Anh VuCFO, Chief Bus. Officer & Principal Accounting OfficerN/AN/A1973
Dr. Arun Upadhyay Ph.D.Chief Scientific Officer and Head of Research, Devel. & MedicalN/AN/A1982
Ms. Tiffany J. Hamilton M.B.A.Head of Corp. CommunicationsN/AN/AN/A
Ms. Zara GaudiosoAVP, Head of HR & Chief of StaffN/AN/AN/A
Mr. Michael Shine M.B.A.Sr. VP of CommercialN/AN/AN/A
Ms. Jyothy Pillai M.S.Head of Regulatory & QualityN/AN/AN/A
Dr. Huma Qamar CMI, M.D., M.P.H.Head of Clinical Devel. & Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Corporate governance

Ocugen, Inc.’s ISS governance QualityScore as of 1 June 2023 is 9. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.